These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 477313)

  • 1. Bleeding and ovulation control with use of a small contraceptive vaginal ring releasing levonorgestrel and estradiol.
    Toivonen J; Lähteenmäki P; Luukkainen T
    Contraception; 1979 Jul; 20(1):11-8. PubMed ID: 477313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of a contraceptive vaginal ring governed by the pattern of individual uterine bleeding.
    Toivonen J; Lähteenmäki P; Luukkainen T
    Contraception; 1979 Apr; 19(4):401-9. PubMed ID: 455988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravaginal contraception with the synthetic progestin, R2010.
    Toivonen J
    Contraception; 1979 Nov; 20(5):511-8. PubMed ID: 527342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD.
    Nilsson CG; Lähteenmäki P; Luukkainen T
    Contraception; 1980 Mar; 21(3):225-33. PubMed ID: 6771090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pituitary and gonadal function during the use of norgestrelestradiol vaginal rings.
    Toivonen J; Lähteenmäki P; Luukkainen T
    Contraception; 1978 Sep; 18(3):201-11. PubMed ID: 720065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of a contraceptive vaginal ring releasing norethindrone and estradiol: ovarian function, bleeding control and lipoprotein patterns.
    Victor A; Lithell H; Selinus I; Vessby B
    Ups J Med Sci; 1984; 89(2):179-88. PubMed ID: 6380076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pituitary and gonadal function during the use of progesterone- or progesterone-estradiol-releasing vaginal rings.
    Toivonen J
    Int J Fertil; 1980; 25(2):106-11. PubMed ID: 6117523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of ovulation and bleeding with a low levonorgestrel-releasing intrauterine device.
    Nilsson CG; Lähteenmäki P; Luukkainen T
    Contraception; 1980 Feb; 21(2):155-64. PubMed ID: 6768490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and D-norgestrel.
    Mehta S; Joshi UM; Sankolli GM; Adatia A; Donde UM; Saxena BN
    Contraception; 1981 Mar; 23(3):241-50. PubMed ID: 7238044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel.
    Mishell DR; Moore DE; Roy S; Brenner PF; Page MA
    Am J Obstet Gynecol; 1978 Jan; 130(1):55-62. PubMed ID: 619648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the positive feedback of oestradiol during treatment with subcutaneous implants of d-norgestrel.
    Weiner E; Johansson ED; Wide L
    Contraception; 1976 Mar; 13(3):287-98. PubMed ID: 1248256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K; Lunell NO; Zador G
    Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel.
    Elkik F; Basdevant A; Jackanicz TM; Guy-Grand B; Mercier-Bodard C; Conard J; Bardin CW; Corvol P
    J Clin Endocrinol Metab; 1986 Jul; 63(1):29-35. PubMed ID: 3086360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum norethindrone (NET) concentrations following intramuscular NET enanthate injection. Effect upon serum LH, FSH, estradiol and progesterone.
    Goebelsmann U; Stanczyk FZ; Brenner PF; Goebelsmann AE; Gentzschein EK; Mishell DR
    Contraception; 1979 Mar; 19(3):283-313. PubMed ID: 572279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary and ovarian function and clinical performance during the use of a levonorgestrel-releasing intracervical contraceptive device.
    Kurunmäki H; Toivonen J; Lähteenmäki PL; Luukkainen T
    Contraception; 1984 Jan; 29(1):31-43. PubMed ID: 6428806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of a biodegradable contraceptive capsule (Capronor) containing levonorgestrel on gonadotropin, estrogen, and progesterone levels.
    Ory SJ; Hammond CB; Yancy SG; Hendren RW; Pitt CG
    Am J Obstet Gynecol; 1983 Mar; 145(5):600-5. PubMed ID: 6402933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracervical release of levonorgestrel for contraception.
    Kurunmäki H; Toivonen J; Lähteenmäki P; Luukkainen T
    Contraception; 1981 May; 23(5):473-85. PubMed ID: 6793299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.